INCLIVA Health Research Institute (of the Hospital Clínico de Valencia), the Polytechnic University of Valencia, the University of Valencia and the Fisabio-Hospital Dr. A study by Peset shows that gold and cerium Au/CeO2 nanoparticles with a gold content of only 0.82% exert antioxidant and anti-inflammatory actions in leukocyte-endothelium interactions of patients with type 2 diabetes (DM2). In this way, a protective role is created against the appearance of atherosclerosis and heart diseases.
Leukocyte-endothelium interactions are a series of processes that occur when leukocytes, also known as white blood cells, move through the endothelial layer that lines blood vessels in search of sites of inflammation or infection. Huh. These interactions are an essential part of the immune system and play an important role in protecting the body from infection and disease.
The aim of this study was to evaluate the effects of gold and cerium Au/CeO2 nanoparticles with different degrees of gold purity (10, 4.4, 1.79 and 0.82%) on leukocyte-endothelium interaction and inflammation in patients with DM2. Its principal investigator is Dr. Victor Manuel Victor Gonzalez, part of the INCLIVA “Vascular Function Research Group” (coordinated by Dr. José M. Villa Salinas), and the “Group of Molecular Mechanisms Underlying Diabetes”. , Fisabio- Se Hospital Dr. Peset.
The first results of this research have recently been published in the journal Antioxidants, under the title ‘Gold nanoparticles supported on ceria nanoparticles modulate leukocyte-endothelium cell interactions and inflammation in type 2 diabetes’.
A prospective and observational study was conducted in a group of 57 patients with DM2 at the Endocrinology Service of the Doctor Peset University Hospital in Valencia—and diagnosed according to the criteria of the American Diabetes Association—and 51 healthy people.
UPV researcher Hermenegildo García at the Institute of Chemical Technology (UPV-CSIC); Susana Rovira Lopis, from the University of Valencia, and Pedro Díaz Pozo and Milagros Rocha Barajas, both from the FISABIO-Hospital Dr. Peset. The researchers are affiliated with the Center for Networked Biomedical Research in Liver and Digestive Diseases (CIBEREHD) and the Center for Networked Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBERBBN).
DM2 is a serious health problem worldwide, as its prevalence is increasing and implies a reduction in life expectancy. Oxidative stress—which occurs when there is an imbalance between the production of free radicals and the body’s ability to fight them with antioxidants, leading to premature aging, heart disease, certain types of cancer and other chronic diseases—and mitochondrial degradation There are health problems. Insulin resistance has been associated with the presence of DM2 and cardiometabolic diseases.
The use of nanoparticles in biomedicine is increasing, with a wide range of potential applications including antioxidant therapy, bioimaging and drug delivery. Among the various types of nanoparticles, cerium (CeO) nanoparticles are particularly promising because of their versatility, biocompatibility, and physico-chemical properties.
Additionally, CeO2 has been shown to have antioxidant properties and can be used to combat oxidative stress. This antioxidant capacity can be enhanced when the nanoparticles are combined with certain metals such as silver, platinum or gold.
“To obtain maximum antioxidant activity, the gold nanoparticles must be a few nanometers in diameter, with a narrow size distribution, and stable against agglomeration. The gold particles are obtained by precisely depositing them. For this reason, the work is multidisciplinary and requires a team with the ability to prepare this type of material, such as ITQ”, highlights Hermenegildo García .
Although the etiology of insulin resistance and DM2 is complex, various studies supported the potential of gold nanoparticles as antioxidants in models of DM2, among others, but whether they can provide benefits to people with the disease remains to be seen. was still unknown.
The research has received funding of 207,157 euros from the Generalitat Valenciana (Prometio/2019/027) and 183,920 euros from the Carlos III Health Institute (PI19/0838).